Compare Enveric Biosciences Inc (ENVB) vs Alliant Energy Corporation (LNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Alliant Energy Corporation — how do they compare? Enveric Biosciences Inc trades at $1.48 (market cap $6.80M), while Alliant Energy Corporation trades at $65.85 (market cap $16.99B). The key difference: Alliant Energy Corporation is far larger — about 2498.5× Enveric Biosciences Inc's market cap, and Alliant Energy Corporation pays a 3.27% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Alliant Energy Corporation for 64 Days on average.
| ENVB | LNT | |
|---|---|---|
Market Cap | $6.80M | $16.99B |
Volume | 64,867 | 2,488,387 |
Sector | Health | Utilities |
52-Week High | $10.80 | $78.03 |
52-Week Low | $1.27 | $63.21 |
Typical Hold Time | 14 Days | 64 Days |
Enterprise Value | -$1.49M | $29.08B |
Dividend Yield | — | 3.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.48, down 1.0% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows negative profitability with ROE at -235.48% and ROA at -193.53%, though it has beaten EPS expectations for four consecutive quarters. Recent developments include patent allowances for non-hallucinogenic therapeutics and positive preclinical data for EB-003.
While analyst consensus is 75% buy with no sell ratings, fundamental weaknesses in revenue generation and negative cash flow from operations pose significant risks. The stock's appeal hinges on clinical progress and regulatory milestones, making it suitable for risk-tolerant investors betting on biotech innovation amid high operational and financial volatility.
LNT trades at $65.84, up 0.97% today, with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong earnings beats in recent quarters and maintains solid profitability with an 18.45% net margin. Analyst consensus is bullish with a $77 price target, and institutional interest remains high, evidenced by recent large purchases.
LNT's outlook is supported by a $13.4 billion capital investment plan and growing data center demand, though rising debt levels and competitive pressures present risks. The stock offers a defensive income stream with a consistent dividend, but investors should monitor execution of growth initiatives amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →
